Pfizer Inc v. Changzhou Pharmaceutical Factory

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Pfizer Inc. (Delaware) and PF Prism Imb BV. (Netherlands)
  • Defendant: Changzhou Pharmaceutical Factory (China)
  • Plaintiff's Counsel: Morris, Nichols, Arsht & Tunnell LLP
• Case Identification: 1:26-cv-00440, D. Del., 04/16/2026
• Venue Allegations: Venue is alleged to be proper because the Defendant is a foreign corporation not resident in the United States and may therefore be sued in any judicial district. The complaint also alleges the Defendant has systematic and continuous contacts with Delaware and has not contested personal jurisdiction in the district in prior lawsuits.
• Core Dispute: Plaintiff alleges that Defendant's submission of an Abbreviated New Drug Application (ANDA) to market a generic version of Plaintiff's CIBINQO® (abrocitinib) tablets constitutes an act of patent infringement.
• Technical Context: The technology involves pyrrolo[2,3-d]pyrimidine derivatives, which function as Janus Kinase (JAK) inhibitors for the treatment of immunological conditions such as moderate-to-severe atopic dermatitis.
• Key Procedural History: This is a Hatch-Waxman action filed under 35 U.S.C. § 271(e)(2) in response to Defendant's notice letter, dated March 17, 2026, which included a Paragraph IV certification against the patents-in-suit. The complaint states the patents-in-suit are listed in the FDA's "Orange Book" for CIBINQO®. The action was filed within the 45-day statutory window.

Case Timeline

Date	Event
2013-02-22	Priority Date for '074, '405, and '929 Patents
2015-05-19	'074 Patent Issued
2017-01-17	'405 Patent Issued
2017-01-24	'929 Patent Issued
2026-03-17	Defendant sends Notice Letter to Plaintiff
2026-04-16	Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 9,035,074 - "Pyrrolo[2,3-D]Pyrimidine Derivates"

• Patent Identification: U.S. Patent No. 9,035,074, titled "Pyrrolo[2,3-D]Pyrimidine Derivates," issued May 19, 2015.

The Invention Explained

• Problem Addressed: The patent addresses the need for new compounds that selectively inhibit specific Janus Kinase (JAK) enzymes, particularly JAK1 over JAK2 '074 Patent, col. 1:50-55 This selectivity is desirable to achieve therapeutic effects for immune disorders while avoiding potential side effects associated with inhibiting JAK2, which is involved in erythropoietin (EPO) and thrombopoietin (TPO) signaling '074 Patent, col. 2:1-9
• The Patented Solution: The patent discloses a class of pyrrolo[2,3-d]pyrimidine derivatives, claimed as compounds of Formula I, that function as JAK inhibitors '074 Patent, abstract '074 Patent, col. 2:16-18 The specification details the synthesis of numerous example compounds, including the compound that would become known as abrocitinib, and provides data on their inhibitory activity against various JAK enzymes '074 Patent, col. 31:51-64 '074 Patent, col. 64:1-21
• Technical Importance: Developing selective JAK1 inhibitors represented a significant advance in treating autoimmune and inflammatory diseases, offering a targeted mechanism to modulate immune responses. '074 Patent, col. 2:1-9

Key Claims at a Glance

• The complaint does not specify which claims are asserted, alleging infringement of "one or more claims" ('074 Patent, ¶34). Independent claim 1 is representative.
• Independent Claim 1 recites:
  • A compound of formula I, or a pharmaceutically acceptable salt thereof, with a core pyrrolo[2,3-d]pyrimidine structure.
  • The structure is defined by multiple variable substituent groups (R¹, R², R³, R⁴, X, and Y), which can be selected from various specified chemical moieties.

U.S. Patent No. 9,545,405 - "Pyrrolo[2,3-D]Pyrimidine Derivates"

• Patent Identification: U.S. Patent No. 9,545,405, titled "Pyrrolo[2,3-D]Pyrimidine Derivates," issued January 17, 2017.

The Invention Explained

• Problem Addressed: The '405 patent, which is a continuation of the application leading to the '074 patent, addresses the same technical problem: the need for selective JAK1 inhibitors to treat various immune-mediated diseases, including atopic dermatitis '405 Patent, col. 3:40-44
• The Patented Solution: The patent claims methods of treating specific disorders by administering a therapeutically effective amount of a pyrrolo[2,3-d]pyrimidine derivative '405 Patent, abstract '405 Patent, claim 1 The patent describes how these compounds function as JAK inhibitors to alleviate symptoms associated with diseases like atopic dermatitis '405 Patent, col. 3:37-44
• Technical Importance: The invention provides a specific therapeutic application for the class of selective JAK1 inhibitors, tying the chemical compounds to the treatment of recognized medical conditions like atopic dermatitis. '405 Patent, col. 15:60-65

Key Claims at a Glance

• The complaint alleges infringement of "one or more claims" ('405 Patent, ¶54). Independent claim 1 is representative.
• Independent Claim 1 recites:
  • A method of treating a disorder or condition selected from atopic dermatitis, eczema, psoriasis, and pruritus in a mammal.
  • The method comprises administering to the mammal a therapeutically effective amount of a compound of formula I (or a salt thereof), which is a pyrrolo[2,3-d]pyrimidine derivative.

U.S. Patent No. 9,549,929 - "Pyrrolo[2,3-D]Pyrimidine Derivates"

• Patent Identification: U.S. Patent No. 9,549,929, titled "Pyrrolo[2,3-D]Pyrimidine Derivates," issued January 24, 2017.

The Invention Explained

• The '929 patent is a divisional of the application that led to the '074 and '405 patents. It addresses the same technical problem of needing selective JAK1 inhibitors '929 Patent, col. 1:49-54 and provides a solution in the form of specific pyrrolo[2,3-d]pyrimidine compounds and methods of their use '929 Patent, abstract

Key Claims at a Glance

• Asserted Claims: The complaint asserts infringement of "one or more claims" ('929 Patent, ¶74). Independent claims 1 and 15 are asserted.
• Accused Features: The accused features are the manufacture, use, or sale of the Changzhou ANDA product, which contains abrocitinib, for the treatment of atopic dermatitis, as allegedly instructed by its proposed labeling ('929 Patent, ¶¶72, 74).

III. The Accused Instrumentality

Product Identification

The accused instrumentality is Changzhou Pharmaceutical Factory's ANDA Product, identified as ANDA No. 221267 for abrocitinib tablets in 50 mg, 100 mg, and 200 mg dosages Compl. ¶18

Functionality and Market Context

The complaint alleges the Changzhou ANDA Product is a generic copy of Plaintiffs' CIBINQO® tablets Compl. ¶19 CIBINQO® (abrocitinib) is a prescribed treatment for adult and pediatric patients aged 12 and older with refractory, moderate-to-severe atopic dermatitis Compl. ¶16 The filing of the ANDA itself, seeking FDA approval prior to the expiration of the patents-in-suit, is the statutory act of infringement that gives rise to this action Compl. ¶32

No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint does not provide a detailed claim chart but alleges that the Defendant's ANDA Product is a generic copy of CIBINQO® (abrocitinib) tablets Compl. ¶¶18-19 It further states that in its Notice Letter, the Defendant "does not contest infringement of one or more claims" of the patents-in-suit Compl. ¶34 Compl. ¶54 Compl. ¶74 The infringement theory is that the Defendant's submission of an ANDA for a product containing the patented compound (abrocitinib) is an act of infringement under 35 U.S.C. § 271(e)(2)(A).

'074 Patent Infringement Allegations

(Based on representative Independent Claim 1)

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A compound of formula I, or a pharmaceutically acceptable salt thereof...	The Changzhou ANDA product is alleged to contain abrocitinib, which is a compound falling within the scope of formula I.	¶¶18-19	col. 31:51-64

'405 Patent Infringement Allegations

(Based on representative Independent Claim 1)

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method of treating a disorder or condition selected from the group consisting of atopic dermatitis...	The complaint alleges the proposed labeling for the Changzhou ANDA Product will instruct physicians and patients to use it to treat atopic dermatitis.	¶¶16, 18, 54	col. 3:40-44
in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of a compound of formula I...	The Changzhou ANDA Product is alleged to contain a therapeutically effective amount of abrocitinib, a compound of formula I, for administration to mammals, including humans.	¶18	col. 15:60-65

Identified Points of Contention

• Scope Questions: The complaint states that the Defendant "does not contest infringement" for any of the patents-in-suit Compl. ¶34 Compl. ¶54 Compl. ¶74 This suggests that the primary legal battle will not be over claim scope or infringement, but rather over the validity and/or enforceability of the asserted patents, which the Defendant challenged in its Paragraph IV certification Compl. ¶20
• Technical Questions: The central technical question for infringement-whether the defendant's proposed generic product is bioequivalent to and contains the same active ingredient as the branded product-appears to be uncontested according to the complaint. The case will therefore likely depend on evidence related to patent validity, such as prior art or enablement, which is not detailed in the complaint.

V. Key Claim Terms for Construction

The complaint does not identify any specific claim terms as being in dispute, and alleges that infringement itself is not contested Compl. ¶34 Compl. ¶54 Compl. ¶74 Therefore, claim construction may not be a central issue for the infringement analysis. However, should the Defendant pursue its invalidity or non-infringement defenses, the following terms from the representative claims may become significant.

The Term: "atopic dermatitis" (['405 Patent, claim 1](https://ex:cit:10))

• Context and Importance: The scope of this term is critical for the method-of-use claims. Practitioners may focus on this term to determine whether the condition treated by the accused product, as described in its label, falls squarely within the patent's definition of the claimed indication.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The specification describes atopic dermatitis as part of a larger class of "skin diseases, conditions or disorders" for which the invention may be useful, potentially supporting a broad reading of the term '405 Patent, col. 18:2-4
  • Evidence for a Narrower Interpretation: The patent also provides a more specific context, tying the condition to pruritus and allergic reactions, which could be argued to limit the scope to specific subtypes of dermatitis characterized by these features '405 Patent, col. 18:5-12

The Term: "therapeutically effective amount" (['405 Patent, claim 1](https://ex:cit:10))

• Context and Importance: This term is fundamental to any method of treatment claim and is often a point of contention in validity and infringement disputes. Its definition is crucial for determining whether the dosage specified in the accused product's label constitutes an infringing use.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The patent defines the term broadly as an amount capable of preventing or improving the severity of the disorder while avoiding adverse side effects, which could encompass a wide range of dosages '405 Patent, col. 3:63-67
  • Evidence for a Narrower Interpretation: The specification provides specific exemplary dosage ranges, such as "about 0.01 to about 100 mg/kg of body weight/day," and more preferred narrower ranges '405 Patent, col. 15:61-67 A party could argue these examples implicitly limit the scope of a "therapeutically effective amount" to these disclosed ranges.

VI. Other Allegations

• Indirect Infringement: The complaint alleges that upon FDA approval, Changzhou will actively induce infringement by encouraging and instructing physicians and patients, through the product's proposed labeling, to use the generic product in an infringing manner to treat atopic dermatitis Compl. ¶74 It also alleges contributory infringement on the basis that the ANDA product is especially made for infringing the patents and is not suitable for a substantial non-infringing use Compl. ¶¶37, 57, 77
• Willful Infringement: The complaint alleges willful infringement based on Changzhou's "full knowledge" of the patents-in-suit, as evidenced by its submission of a Paragraph IV certification, and its continued intent to market the ANDA product "without a reasonable basis for believing" it would not be liable for infringement Compl. ¶¶35, 55, 75

VII. Analyst's Conclusion: Key Questions for the Case

The complaint's repeated assertion that infringement is uncontested focuses the dispute squarely on the patents' validity and enforceability. The key questions for the case are therefore likely to be:

1. A core issue will be one of patent validity: can the Defendant prove by clear and convincing evidence that the asserted claims of the '074, '405, and '929 patents are invalid for reasons such as anticipation, obviousness, or lack of enablement, as asserted in its Paragraph IV certification?
2. A secondary issue will be one of willfulness and remedies: if the patents are found valid and infringed, did the Defendant's filing of its ANDA after providing a Paragraph IV notice constitute willful infringement, thereby justifying enhanced damages or an award of attorneys' fees?
3. A key evidentiary question for the method-of-use claims will be one of label-directed infringement: assuming infringement becomes contested, does the specific language in the Defendant's proposed product label direct medical professionals and patients to administer abrocitinib in a manner that practices every step of the asserted method claims?